Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

23.1%

6 terminated/withdrawn out of 26 trials

Success Rate

72.7%

-13.8% vs industry average

Late-Stage Pipeline

2 trials in Phase 3/4

Results Transparency

63%

10 of 16 completed trials have results

Key Signals

1 recruiting10 with results

Enrollment Performance

Analytics

Phase 2

8(36.4%)

N/A

6(27.3%)

Phase 1

5(22.7%)

Phase 3

2(9.1%)

Early Phase 1

1(4.5%)

22Total

Phase 2(8)

N/A(6)

Phase 1(5)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT05063565Phase 2Active Not Recruiting

TheraSphere With Durvalumab and Tremelimumab for HCC

Role: collaborator

NCT04701918Phase 2Completed

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Role: collaborator

NCT04362436Phase 2Completed

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets

Role: collaborator

NCT04069468Completed

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

Role: collaborator

NCT04108481Phase 1Terminated

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

Role: collaborator

NCT04197336Not ApplicableCompleted

Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)

Role: collaborator

NCT01839877Phase 2Completed

Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study

Role: collaborator

NCT01556490Not ApplicableCompleted

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Role: collaborator

NCT02960620Unknown

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Role: collaborator

NCT01483027Not ApplicableCompleted

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

Role: collaborator

NCT00844883Phase 2Completed

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma

Role: collaborator

NCT00261378Phase 2Completed

Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation

Role: collaborator

NCT00844233Phase 1Completed

Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer

Role: collaborator

NCT03291379Early Phase 1Completed

Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies

Role: collaborator

NCT00932438Phase 1Completed

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

Role: collaborator

NCT03295006Completed

A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC

Role: collaborator

NCT03516695Terminated

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

Role: collaborator

NCT01887717Phase 3Terminated

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Role: collaborator

NCT03686709Not ApplicableRecruiting

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment